/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

H

Haruko Daga

Osaka City General Hospital(JP)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

196

Papers

2.9K

Citations

26

h-index

49

i10-index

Haruko Daga is an academic researcher from Osaka City General Hospital. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Research Studies & Lung Cancer Diagnosis and Treatment. The author has an h-index of 26, co-authored 167 publications.

ORCID: 0000-0002-5191-6233

Research Topics

Lung Cancer Treatments and Mutations Lung Cancer Research Studies Lung Cancer Diagnosis and Treatment Colorectal Cancer Treatments and Studies Cancer Genomics and Diagnostics

Papers by this author

works

Trastuzumab emtansine for patients with non–small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations

2021 · European Journal of Cancer · 74 citations

https://doi.org/10.1016/j.ejca.2021.11.021

Eiji Iwama Yoshitaka Zenke Shunichi Sugawara Haruko Daga

Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L)

2019 · Clinical Lung Cancer · 11 citations

https://doi.org/10.1016/j.cllc.2019.03.002

Hiroaki Akamatsu Shunsuke Teraoka Satoshi Morita Nobuyuki Katakami

First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

2023 · International Journal of Clinical Oncology · 11 citations

https://doi.org/10.1007/s10147-023-02390-2

Makoto Nishio Yuichiro Ohe Satoshi Ikeda Toshihide Yokoyama

Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study

2024 · ESMO Open · 6 citations

https://doi.org/10.1016/j.esmoop.2024.103642

Seiji Niho Yasuhiro Gotô R. Toyozawa Haruko Daga

Efficacy of ramucirumab combined with erlotinib or osimertinib in untreated EGFR-mutated NSCLC patients with asymptomatic brain metastases: insights from molecular biomarkers in the RELAY-brain trial

2025 · Investigational New Drugs · 1 citations

https://doi.org/10.1007/s10637-025-01505-y

Hiroyasu Kaneda Haruko Daga Asuka Okada Yuki Nakatani

[Evaluation of recurrence rates on change in hormone receptor and human epidermal growth factor receptor 2 status after neo-adjuvant chemotherapy in breast cancer patients].

2014 · PubMed · 0 citations

Shinya Tokunaga Katsumi Ikeda Yoshinari Ogawa Hiroko Fukushima

Research topics

topics

Lung Cancer Treatments and Mutations

Lung Cancer Research Studies

Lung Cancer Diagnosis and Treatment

Colorectal Cancer Treatments and Studies

Cancer Genomics and Diagnostics

Chat about Author

Papers

Chat

Click to start Chat